Compendium of current complement therapeutics
This is the single most important section for anyone weighing the risks of BPC-157, and the honest answer is uncomfortable: there are zero completed Phase III human clinical trials for BPC-157, and the peptide has never received marketing approval from any major regulator
FDAs injectable-route concern highlights limited human safety data, aggregation risk, and peptide-related impurity concerns [8]
Starting at $79/ mo Support mental clarity, focus, and cognitive energy with an easy, injection-free way to boost NAD+, designed to support brain pathways and sharper thinking on the go
Please retain your receipt or proof of purchase
People with asthma should avoid inhaled forms and discuss oral use with their doctor